🔗 Share this article

Given that the United States undertakes unprecedented changes to its immunization schedules, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about Covid shots during the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her short tenure at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Health officials had intended to reveal major changes to the childhood vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a significant shift that would put the US at odds with a large portion of the world with no evidence for improved outcomes. The planned update has been delayed until the next year.

Instead of Vinay Prasad, Høeg is scheduled to present at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to lead the division this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for ending some childhood shot schedules in the US so as to align more like Denmark, a society with nationalized medicine and a population approximately the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent track record in drug development, approval processes or management, which has been customary for previous heads of the biologics center. She has served at the FDA as a senior adviser to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a scientific study. She is not versed in running a sizeable institution. She is not an expert in industry regulation.”

Former heads of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she pointed out.

“The public just pays attention on the innovative therapies, but the generic program approves a multitude of generic drugs. There’s a biosimilars program, OTC medication office and more, and every single one have to be supervised,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant administrative aspect to the position, which manages over 5,000 employees. “It is a huge management job, if you perform it correctly,” the former official said.

Official Statement and Controversial Initiatives

Regarding inquiries about Høeg’s qualifications and whether this appointment signifies greater collaboration among agency officials on vaccines, a representative stated that the “inquiries are based on incorrect premises”.

“This background aligns with the duties of her position,” the official explained, noting the time Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial expedited drug-approval program that apparently concerned her former heads. “How are these therapies being picked for this fast-track system? Who makes the calls?” Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the FDA appears to be shifting towards less stringent oversight of all drugs, with the exception of shots.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if troubling, history, some experts have noted. She authored a research paper using unconfirmed volunteer-provided data to assess the rate of heart inflammation following COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming federal leadership encompassed changing regulations for novel immunizations and discontinuing “unnecessary” vaccines, she stated following the vote on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring adolescent males from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her conclusions and reverse-engineers to accommodate the evidence in a extremely misleading, dishonest fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow skeptics, {like|